Claims
- 1. A benzonorbornene derivative of formula (I) or an isomer or salt thereof having the formula ##STR42## wherein R.sub.1, R.sub.3 and R.sub.4 each independently represent hydrogen, C.sub.1 -C.sub.8 alkoxy, halogen, C.sub.1 -C.sub.8 alkyl, C.sub.1 -C.sub.8 acyloxy or hydroxyl,
- R' is hydrogen or C.sub.1 -C.sub.6 alkyl and
- A.sub.3 is --CH.sub.2 OR' or --COR.sub.7 wherein R.sub.7 is hydroxyl, C.sub.1 -C.sub.6 alkoxy, arloxy or ##STR43## wherein r' and r" each independently represent hydrogen, linear or branched C.sub.1 -C.sub.6 alkyl substituted or not by one or more hydroxyl groups or r' and r" together with the nitrogen atom to which they are attached form a heterocycle,
- with the proviso that when R' represents hydrogen or CH.sub.3 and R.sub.1 equals R.sub.4 equals hydrogen and R.sub.3 equals hydrogen or CH.sub.3 and A.sub.3 is other than --COR.sub.7 wherein R.sub.7 is hydroxyl, C.sub.1 -C.sub.6 alkoxy, aryloxy or ##STR44## wherein r' is linear or branched C.sub.1 -C.sub.6 and R" is hydrogen or linear or branched C.sub.1 -C.sub.6 alkyl.
- 2. The benzonorbornene derivative of claim 1 wherein R.sub.1, R.sub.3 and R.sub.4 represent hydrogen, C.sub.1 -C.sub.8 alkyl, C.sub.1 -C.sub.8 alkoxy or halogen; R' represents hydrogen or C.sub.1 -C.sub.6 alkyl and A.sub.3 represents --COR.sub.7 wherein R.sub.7 is hydroxyl or C.sub.1 -C.sub.6 alkoxy.
- 3. The benzonorbornene derivative of claim 1 which is 4-[cis-2-(1,4-dibromo-5,8-methano-5,6,7,8-tetrahydro-2-naphthyl) propenyl]benzoic acid.
- 4. The benzonorbornene derivative of claim 1 which is ethyl 4-[cis-2-(1,4-dibromo-5,8-methano-5,6,7,8-tetrahydro-2-naphthyl) propenyl]benzoate.
- 5. The benzonorbornene derivative of claim 1 which is ethyl 4-[cis-2-(3-isobutyl-5,8-methano-5,6,7,8-tetrahydro-2-naphthyl) propenyl]benzoate.
- 6. The benzonorbornene derivative of claim 1 which is 4-[cis-2-(3-isobutyl-5,8-methano-5,6,7,8-tetrahydro-2-naphthyl) propenyl]benzoic acid.
- 7. The benzonorbornene derivative of claim 1 which is ethyl 4-[cis-2-(5,8-methano-5,6,7,8-tetrahydro-2-naphthyl)-3-methylbutenyl]benzoate.
- 8. The benzonorbornene derivative of claim 1 which is ethyl 4-[trans-2-(5,8-methano-5,6,7,8-tetrahydro-2-naphthyl)-3-methylbutenyl]benzoate.
- 9. The benzonorbornene derivative of claim 1 which is 4-[trans-2-(5,8-methano-5,6,7,8-tetrahydro-2-naphthyl)-3-methylbutenyl]benzoic acid.
- 10. The benzonorbornene derivative of claim 1 which is 4-[cis-2-(1,4-dimethoxy-5,8-methano-5,6,7,8-tetrahydro-2-naphthyl) propenyl]benzoic acid.
- 11. A composition suitable for pharmaceutical use comprising, in a pharmaceutically acceptable carrier, at least one benzonorbornene derivative of claim 1.
- 12. The composition of claim 11 in a form suitable for topical administration, wherein said benzonorbornene derivative is present in an amount ranging from 0.0005 to 2 percent by weight of said composition.
- 13. The composition of claim 12 wherein said benzonorbornene derivative is present in an amount ranging from 0.002 to 1 percent by weight of said composition.
- 14. The composition of claim 12 in the form of an ointment, gel, cream, pomade, powder, tincture, solution, suspension, emulsion, lotion, spray, patch or saturated pad.
- 15. The composition of claim 11 in a form suitable for enteral administration.
- 16. The composition of claim 11 in a form suitable for oral administration.
- 17. The composition of claim 11 in the form of a solution or suspension suitable for parenteral administration.
- 18. The composition of claim 17 wherein said benzonorbornene derivative is present in an amount ranging from 0.01 to 1 mg per ml of said solution or suspension.
- 19. The composition of claim 11 in a form suitable for ocular administration.
- 20. The composition of claim 11 wherein said pharmaceutically acceptable carrier is at least one of water, gelatin, lactose, starch, talc, liquid petrolatum, gum arabic, polyalkylene glycol and magnesium stearate.
- 21. The composition of claim 11 which also includes, as an inert or pharmacodynamically active additive, one or more of a hydrating agent, an antiseborrhoeic agent, an antibiotic, an anti-acne agent, an agent promoting regrowth of hair, an anti-inflammatory agent, a carotenoid, a antipsoriatic agent, a flavoring agent, a preservative, a stabilizer, a moisture-regulating agent, a pH-regulating agent, an osmotic pressure modifying agent, a UV-A or UV-B screening agent or an antioxidant.
- 22. A cosmetic composition comprising in a cosmetically acceptable carrier at least one benzonorbornene derivative of claim 1.
- 23. The cosmetic composition of claim 22 wherein said benzonorbornene derivative is present in an amount ranging from 0.0005 to 2 percent by weight of said composition.
- 24. The cosmetic composition of claim 23 wherein said benzonorbornene derivative is present in an amount ranging from 0.01 to 1 percent by weight of said composition.
- 25. The cosmetic composition of claim 22 in the form of a lotion, a gel, a cream, a soap or a shampoo.
- 26. The cosmetic composition of claim 22, which also includes, as an inert or cosmetically active additive, one or more of a hydrating agent, an antiseborrhoeic agent, an antibiotic, an anti-acne agent, an agent promoting growth of hair, an anti-inflammatory agent, a carotenoid, an antipsoriatic agent, a flavoring agent, a preservative, a stabilizer, a moisture-regulating agent, a pH-regulating agent, an osmotic pressure modifying agent or an antioxidant.
- 27. A method for the treatment of a dermatological complaint connected with a keratinization (differentiation-proliferation) disorder, of dermatological or other complaints with an inflammatory and/or immuno-allergic component, of benign or malignant dermatological proliferations, of rheumatoid psoriasis or of ophthalmological complaints, which comprises administering to a subject suffering therefrom or liable thereto an effective amount of the benzonorbornene derivative of claim 1.
- 28. The method of claim 27 wherein from 2 mg to 2 g of said derivative is administered per day per kg of body weight.
Priority Claims (2)
Number |
Date |
Country |
Kind |
85531 |
Sep 1984 |
LUX |
|
85700 |
Dec 1984 |
LUX |
|
Parent Case Info
This is a, now U.S. Pat. No. 5,053,547 division of application Ser. No. 07/436,242, filed Nov. 14, 1989, which is a division of application Ser. No. 07/218,204, filed Jul. 12, 1988, now U.S. Pat. No. 4,931,589 which is a continuation of Ser. No. 06/772,525, filed Sep. 4, 1985, now U.S. Pat. No. 4,783,549.
Non-Patent Literature Citations (4)
Entry |
CA 102(3):24246k 1984. |
CA 101(21):192241c 1984. |
Dawson, et al., Conformationally Registered Retinoids; J. Med. Chem. vol. 27, pp.1516-1531, 1984. |
Dawson, et al., A Method for the Stereoselective Synthesis of (E)-Methylstilbene Retinoids; J. Org. Chem. vol. 49, pp. 5265-5267, 1984. |
Divisions (2)
|
Number |
Date |
Country |
Parent |
436242 |
Nov 1989 |
|
Parent |
218204 |
Jul 1988 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
772525 |
Sep 1985 |
|